Amazon and Caremark could haunt CVS/Aetna
In the coming months, antitrust enforcers at the Department of Justice will decide whether and how CVS Health’s $69 billion acquisition of Aetna might harm consumers – a question shaded by a history of consolidation across the healthcare industry and the potential for new, powerful entrants to disrupt the industry.
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10